Clinical TrialApr 14, 2026, 08:02 AM
BioVie's Parkinson's Study Abstract Accepted for AAN Meeting
AI Summary
BioVie Inc. announced the acceptance of an abstract from its SUNRISE-PD study on bezisterim (NE3107) for Parkinson's Disease at the American Academy of Neurology Annual Meeting. The abstract, summarizing initial patient data, will be presented as a poster on April 20, 2026. Topline results from the SUNRISE-PD study are anticipated in mid-2026, marking a significant step in the development of this potential therapy.
Key Highlights
- BioVie's SUNRISE-PD study abstract accepted for AAN Annual Meeting.
- Abstract titled "A Study of NE3107 (Bezisterim) in Early Parkinson's Disease (SUNRISE-PD): Baseline Demographics and Characteristic."
- Poster presentation on April 20, 2026, during Movement Disorders Session.
- Topline results from SUNRISE-PD study expected in mid-2026.
- Bezisterim (NE3107) is an oral drug for neurological and neurodegenerative diseases.
Price Impact
More from BIVI